Regenerative therapies with growth factors, cytokines, exosomes and stem cells represent cutting edge options that are on the cusp of mainstream deployment. The ethical concerns over fetal involvement have been eliminated with the latest procedures that either use the patient’s own tissue elements (blood, adipose or bone marrow), amniotic fluid or umbilical cord tissue collected from consenting donors after scheduled C-sections.